Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

KPV Peptide Research | What Cell and Mouse Studies Show

RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE: This page is for qualified laboratory personnel working under institutionally authorized in-vitro protocols or institutionally approved animal-study protocols. It is not a guide for personal preparation or home use.

Nothing on this page may be used or converted for human use, veterinary use, diagnosis, treatment, cosmetic use, or any other consumer application.

KPV is a three-amino-acid peptide with the sequence Lys-Pro-Val. Its amino-acid sequence corresponds to residues 11–13 of α-melanocyte-stimulating hormone.

The free peptide discussed here is H-Lys-Pro-Val-OH, which should be distinguished from the amidated C-terminal form present in mature α-MSH.

Published research has studied KPV in cell cultures and mouse models.

These studies do not show that KPV is safe or effective for use in people or animals outside a research setting.

KPV Peptide Research丨What Cell and Mouse Studies Show

What KPV Is

Item Information What to check
Name KPV; Lys-Pro-Val; corresponds to α-MSH residues 11–13 at the sequence level Check that the product is unmodified KPV and not a related compound.
Sequence H-Lys-Pro-Val-OH This is the free peptide sequence.
Molecular formula C16H30N4O4 This formula does not include acetate, trifluoroacetate, water, or another counterion.
Average molecular weight 342.43 g/mol A salt or hydrated form may have a different gross composition. Do not assume a fixed salt molecular weight unless counterion stoichiometry and water content are defined or analytically quantified.
CAS number 67727-97-3 Confirm the CAS number and molecular form on the lot-specific COA.

NCBI PubChem lists Lys-Pro-Val under CID 125672 with the formula C16H30N4O4, a molecular weight of 342.43 g/mol (monoisotopic mass 342.22670545 Da), XLogP3 −3.5, and CAS number 67727-97-3.[1]

The figures above describe the free peptide. A supplied product may contain acetate, trifluoroacetate, water, or another counterion.

For that reason, concentration calculations should use the molecular form and peptide content shown on the COA for the actual batch.

What Cell Studies Found

Intestinal and immune-cell studies

Dalmasso and colleagues studied KPV in Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and in Jurkat T cells. They used uptake tests, an NF-κB reporter assay, western blotting, RT-PCR, and ELISA.

In these test systems, KPV uptake was linked to the PepT1 peptide transporter.

The study also reported lower NF-κB and MAPK pathway activity and lower IL-8-related results under the stated test conditions.[2]

This does not mean that PepT1 is the only way KPV can enter every type of cell. Transporter levels, pH, concentration, cell type, and competing peptides can change uptake.

A study that claims PepT1 dependence should include a suitable transporter control.

Bronchial epithelial-cell study

Land studied KPV in the immortalized human bronchial epithelial cell line 16HBE14o-. Under TNF-α or respiratory syncytial virus challenge conditions, the study reported lower NF-κB reporter activity, lower IL-8 and eotaxin release, and lower MMP-9 activity.

It also reported less movement of the NF-κB p65/RelA protein into the nucleus.[3]

The same paper suggested that KPV may interfere with the interaction between p65/RelA and importin-α3, a protein involved in moving p65/RelA into the nucleus. The proposed location near armadillo repeats 7 and 8 came from modeling and should not be described as a fully proven binding site.

Some location experiments also used tagged molecules, so those results should not be treated as proof that unmodified KPV behaves in exactly the same way.[3]

The paper supports wording such as “KPV was linked to IκBα stabilization under the test conditions.” It does not prove that KPV directly blocks IKK in every cell type or always lowers IκBα phosphorylation.

What Mouse Studies Found

Dalmasso and colleagues also tested KPV in DSS- and TNBS-based mouse models. Kannengiesser and colleagues studied KPV in DSS and CD45RBhigh transfer models.

The papers reported differences in model-specific measures such as tissue changes, inflammatory markers, body-weight changes, and myeloperoxidase activity.[2][4]

The Kannengiesser study found that some results still occurred in mice with a nonfunctional MC1 receptor. The authors described the effect as at least partly independent of MC1R.

This does not prove that KPV has no receptor-related action in every experimental system.[4]

Important: Mouse-model results are not human results. They should be reported as changes in the exact endpoints measured in the study, not as proof that KPV treats, cures, repairs, or prevents a disease.

Do Not Mix KPV with Related Compounds

Lys-D-Pro-Val, often written as KdPV or KDPV, contains D-proline. It is not the same compound as the natural L-proline form of KPV.

A 2001 paper by Haddad et al. studied Lys-D-Pro-Val in a model of foetal alveolar type II epithelial cells, where KDPV suppressed lipopolysaccharide-induced nuclear localization of NF-κB subunits p50, p65, and c-Rel in a dose-dependent manner and inhibited NF-κB DNA-binding activity through reversal of IκB-α phosphorylation and degradation, with subsequent cytosolic IκB-α accumulation.

The same study found that the effect involved IL-1-dependent and prostanoid-dependent mechanisms, with the interleukin-1 receptor antagonist IL-1ra and the cyclo-oxygenase inhibitor indomethacin both blocking LPS-induced NF-κB activation.

These results should be labeled as analog data and should not be presented as direct evidence for unmodified KPV.[5]

The same rule applies to CKPV compounds, KPV dimers, glycosylated KPV analogs, conjugates, and KPV loaded into particles. These materials can have different mass, stability, uptake, and test results.

What Formulation Studies Mean

Laroui and colleagues tested KPV loaded into nanoparticles and placed in a polysaccharide hydrogel. The authors reported that the effective KPV dose delivered in the nanoparticle formulation was approximately 12,000-fold lower than the dose used for free KPV in that specific experimental comparison.

This number belongs only to that formulation and study design.

It is not a general potency ratio for KPV.[6]

Xiao and colleagues studied hyaluronic-acid-functionalized KPV nanoparticles in cell and mouse-model experiments. The reported results belong to the full formulation, including its carrier, surface coating, particle size, and research protocol.

They should not be described as results from free KPV alone.[7]

How to Read a KPV COA

A COA should be read item by item. HPLC purity, mass spectrometry, peptide content, water, counterion, and residual solvents are different tests.

One result cannot replace the others.

COA item What it can show What it cannot show on its own
RP-HPLC purity The relative chromatographic purity or peak-area percentage reported under the stated method, where area normalization is used Exact peptide content, full identity, sterility, or safety
Mass spectrometry Whether an observed ion agrees with the expected molecular mass Complete sequence, stereochemistry, purity, or biological activity
Peptide content How much of the weighed material is reported as peptide, usually on a free-peptide equivalent, counterion-free, or other stated basis Chromatographic purity or activity in a cell assay
Water and counterion Components that can affect gross weight and concentration calculations Identity or activity by themselves
Residual solvents Reported solvent levels under the stated test method A complete quality conclusion if the method and limits are missing

ICH Q6A explains that a specification is made up of tests, test methods, and acceptance criteria, and provides guidance for new drug substances of synthetic chemical origin. ICH Q3C(R9) gives a framework for residual solvents in pharmaceuticals.[8][9]

These ICH documents are included only to explain common quality-control terms. They do not make a research peptide a pharmaceutical product, and a passing COA does not prove that the material is safe or effective for human or veterinary use.

Laboratory Handling Notes

LABORATORY USE ONLY: The notes below are for controlled in-vitro research. They are not human or veterinary dosing instructions.

Do not use or convert them for administration to a person or animal.

Use the storage condition stated on the lot-specific COA or supplier document. If that document calls for storage at −20°C, keep the unopened material dry and protected from light.

Do not claim a fixed shelf life unless it has been supported by stability data for that exact batch and container.

General peptide reconstitution for laboratory research principles do not identify a single solvent or concentration that is correct for every experiment.

Solubility can change with salt form, concentration, pH, buffer, temperature, and ionic strength.

Test a small amount first and record whether the solution is clear and stable under the planned conditions.

Molar concentration calculations:

First determine the basis on which the COA reports peptide content or assay. If peptide content is reported as free-KPV equivalent on a mass basis, calculate:

moles of KPV = weighed sample mass in grams × peptide-content fraction ÷ 342.43 g/mol

molar concentration = moles of KPV ÷ final solution volume in liters

For example, a peptide content of 82% should be entered as 0.82. HPLC area purity should not automatically be substituted for peptide content.

If the COA instead reports an assay on the basis of a defined stoichiometric salt, use the molecular weight and assay basis specified for that salt. Do not assume a fixed acetate, trifluoroacetate, or hydrate molecular weight unless counterion stoichiometry and water content are defined or analytically quantified.

When preparing a target amount of KPV equivalent, the required gross sample mass is:

required gross sample mass = required KPV-equivalent mass ÷ peptide-content fraction

This avoids the common error of mixing a free-peptide-equivalent content value from the COA with a salt total molecular weight in the same calculation, which would double-correct for counterions and water.

Key Limits of the Evidence

  • Cell-culture results apply only to the cell line, stimulus, concentration, and time used in the study.
  • Mouse-model results do not prove an effect in humans or veterinary patients.
  • Results from KdPV, CKPV, dimers, analogs, conjugates, or nanoparticles are not direct results for free KPV.
  • HPLC purity and an expected mass peak do not prove safety, sterility, or biological activity.
  • The published studies do not provide an approved human or veterinary dose, route, or use.

Research References

Note: Some original paper titles contain disease or treatment wording. The titles are listed for accurate citation only and are not product claims.

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 125672, MSH (11–13) / Lys-Pro-Val. NCBI PubChem.
  2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. doi:10.1053/j.gastro.2007.10.026. PubMed PMID 18061177.
  3. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. International Journal of Physiology, Pathophysiology and Pharmacology. 2012;4(2):59–73. PMC3403564.
  4. Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324–331. doi:10.1002/ibd.20334. PubMed PMID 18092346.
  5. Haddad JJE, Lauterbach R, Saadé NE, Safieh-Garabedian B, Land SC. α-Melanocyte-related tripeptide, Lys-D-Pro-Val, ameliorates endotoxin-induced nuclear factor κB translocation and activation: evidence for involvement of an interleukin-1β193–195 receptor antagonism in the alveolar epithelium. Biochemical Journal. 2001;355(Pt 1):29–38. doi:10.1042/bj3550029. Publisher full text.
  6. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology. 2010;138(3):843–853.e1–e2. doi:10.1053/j.gastro.2009.11.003. PubMed PMID 19909746.
  7. Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628–1640. doi:10.1016/j.ymthe.2016.11.020. PubMed PMID 28143741.
  8. International Council for Harmonisation. Q6A: Specifications—Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH Q6A.
  9. International Council for Harmonisation. Q3C(R9): Impurities—Guideline for Residual Solvents. ICH Q3C(R9).

Research Use Only Disclaimer

Research Use Only: All SaiyanMed products are for laboratory research purposes only and not approved for human use. This article provides an informational summary of published preclinical research and general laboratory quality-control considerations.

It is not an experimental protocol or dosing guide and does not constitute medical, clinical, veterinary guidance or treatment advice.